Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC).
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Therapeutic Use
- 22 Mar 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 22 Mar 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 09 Feb 2015 Planned End Date changed from 1 Apr 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History